GraŻyna Sypniewska

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7827459/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. European Heart Journal, 2016, 37, 1944-1958.	2.2	542
2	Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. Clinical Chemistry, 2018, 64, 1006-1033.	3.2	189
3	Metabolic Syndrome and Menopause. Advances in Clinical Chemistry, 2015, 72, 1-75.	3.7	158
4	Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpoints—A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Clinical Chemistry, 2016, 62, 930-946.	3.2	145
5	Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM. Atherosclerosis, 2020, 294, 46-61.	0.8	137
6	Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Clinical Chemistry and Laboratory Medicine, 2020, 58, 496-517.	2.3	119
7	European multicenter analytical evaluation of the Abbott ARCHITECT STAT high sensitive troponin I immunoassay. Clinical Chemistry and Laboratory Medicine, 2014, 52, 1657-65.	2.3	117
8	PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Archives of Medical Science, 2021, 17, 1447-1547.	0.9	78
9	Critical appraisal of inflammatory markers in cardiovascular risk stratification. Critical Reviews in Clinical Laboratory Sciences, 2014, 51, 263-279.	6.1	67
10	Diabetes as a complication of adipose tissue dysfunction. Is there a role for potential new biomarkers?. Clinical Chemistry and Laboratory Medicine, 2013, 51, 177-185.	2.3	65
11	High-sensitivity cardiac troponin assays: From improved analytical performance to enhanced risk stratification. Critical Reviews in Clinical Laboratory Sciences, 2017, 54, 143-172.	6.1	51
12	Defining normality in a European multinational cohort: Critical factors influencing the 99th percentile upper reference limit for high sensitivity cardiac troponin I. International Journal of Cardiology, 2015, 187, 256-263.	1.7	41
13	Biochemical Markers of Bone Cell Activity in Children with Type 1 Diabetes Mellitus. Journal of Pediatric Endocrinology and Metabolism, 2010, 23, 81-6.	0.9	40
14	Association of follicle-stimulating hormone and sex hormone binding globulin with the metabolic syndrome in postmenopausal women. Clinical Biochemistry, 2012, 45, 703-706.	1.9	31
15	25-Hydroxyvitamin D, Biomarkers of Endothelial Dysfunction and Subclinical Organ Damage in Adults With Hypertension. American Journal of Hypertension, 2014, 27, 114-121.	2.0	30
16	Secreted frizzled-related protein 4 (SFRP4) and fractalkine (CX3CL1) — Potential new biomarkers for β-cell dysfunction and diabetes. Clinical Biochemistry, 2014, 47, 529-532.	1.9	29
17	Association of FSH with metabolic syndrome in postmenopausal women: a comparison with CRP, adiponectin and leptin. Biomarkers in Medicine, 2014, 8, 921-930.	1.4	28
18	The quality of the extra-analytical phase of laboratory practice in some developing European countries and Mexico – a multicentric study. Clinical Chemistry and Laboratory Medicine, 2011, 49, 215-228.	2.3	27

GraŻyna Sypniewska

#	Article	IF	CITATIONS
19	Laboratory assessment of cardiometabolic risk in overweight and obese children. Clinical Biochemistry, 2015, 48, 370-376.	1.9	27
20	Diagnostic efficacy of myeloperoxidase for the detection of acute coronary syndromes. European Journal of Clinical Investigation, 2011, 41, 667-671.	3.4	23
21	Plasma midregional proadrenomedullin (MR-proADM) concentrations and their biological determinants in a reference population. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1161-1168.	2.3	23
22	Combined periprocedural evaluation of CRP and TNF-alpha enhances the prediction of clinical restenosis and major adverse cardiac events in patients undergoing percutaneous coronary interventions. International Journal of Molecular Medicine, 2005, 16, 173-80.	4.0	21
23	Value of C-Reactive Protein as a Risk Factor for Acute Coronary Syndrome: A Comparison with Apolipoprotein Concentrations and Lipid Profile. Mediators of Inflammation, 2012, 2012, 1-10.	3.0	19
24	Bone turnover markers and cytokines in joint fluid: Analyses in 10 patients with loose hip prosthesis and 39 with coxarthrosis. Acta Orthopaedica, 2002, 73, 518-522.	1.4	14
25	Establishing reference intervals for galectin-3 concentrations in serum requires careful consideration of its biological determinants. Clinical Biochemistry, 2017, 50, 599-604.	1.9	14
26	Is there an association of allergy and cardiovascular disease?. Biochemia Medica, 2011, 21, 210-218.	2.7	14
27	How Do Apolipoproteins ApoB and ApoA-I Perform in Patients with Acute Coronary Syndromes. Journal of Medical Biochemistry, 2011, 30, 237-243.	1.7	13
28	Effect of second and third generation oral contraceptives on C-reactive protein, lipids and apolipoproteins in young, non-obese, non-smoking apparently healthy women. Clinical Biochemistry, 2010, 43, 626-628.	1.9	12
29	Bone Turnover Markers and Estradiol Level in Postmenopausal Women. Clinical Chemistry and Laboratory Medicine, 2000, 38, 1115-9.	2.3	10
30	Comparison between C-reactive protein and adipocyte fatty acid-binding protein as a component of metabolic syndrome in middle-aged women. Clinical Biochemistry, 2011, 44, 304-306.	1.9	10
31	Association between Fasting Glucose Concentration, Lipid Profile and 25(OH)D Status in Children Aged 9–11. Nutrients, 2018, 10, 1359.	4.1	10
32	The Association between Branched-Chain Amino Acids (BCAAs) and Cardiometabolic Risk Factors in Middle-Aged Caucasian Women Stratified According to Glycemic Status. Nutrients, 2021, 13, 3307.	4.1	10
33	Increased DNA synthesis in adipocytes and capillary endothelium in rat adipose tissue during overfeeding. European Journal of Clinical Investigation, 1987, 17, 202-207.	3.4	9
34	The Use of Biochip Cardiac Array Technology for Early Diagnosis of Acute Coronary Syndromes. Journal of Medical Biochemistry, 2009, 28, 293-299.	1.7	9
35	A-FABP and its association with atherogenic risk profile and insulin resistance in young overweight and obese women. Biomarkers in Medicine, 2013, 7, 723-730.	1.4	8
36	The Kynurenine Pathway in Obese Middle-Aged Women with Normoglycemia and Type 2 Diabetes. Metabolites, 2022, 12, 492.	2.9	8

GraŻyna Sypniewska

#	Article	IF	CITATIONS
37	Impact of lipid markers and high-sensitivity C-reactive protein on the value of the 99th percentile upper reference limit for high-sensitivity cardiac troponin I. Clinica Chimica Acta, 2016, 462, 193-200.	1.1	7
38	Non-fasting lipid profile determination in presumably healthy children: Impact on the assessment of lipid abnormalities. PLoS ONE, 2018, 13, e0198433.	2.5	7
39	Effect of fasting hyperglycemia and insulin resistance on bone turnover markers in children aged 9–11Âyears. Journal of Diabetes and Its Complications, 2021, 35, 108000.	2.3	6
40	Relationships between Bone Turnover Markers and Factors Associated with Metabolic Syndrome in Prepubertal Girls and Boys. Nutrients, 2022, 14, 1205.	4.1	6
41	Serum Anti-M¼llerian Hormone Levels in Patients with Epithelial Ovarian Cancer. International Journal of Endocrinology, 2013, 2013, 1-6.	1.5	5
42	Bone health and hyperglycemia in pediatric populations. Critical Reviews in Clinical Laboratory Sciences, 2020, 57, 444-457.	6.1	5
43	Relationship between Serum Angiopoietin-like Proteins 3 and 8 and Atherogenic Lipid Biomarkers in Non-Diabetic Adults Depends on Gender and Obesity. Nutrients, 2021, 13, 4339.	4.1	5
44	A-FABP Concentration Is More Strongly Associated with Cardiometabolic Risk Factors and the Occurrence of Metabolic Syndrome in Premenopausal Than in Postmenopausal Middle-Aged Women. BioMed Research International, 2014, 2014, 1-10.	1.9	4
45	Gender differences in association of serum nesfatinâ€1 with selected metabolic risk factors in normoglycemic subjects: A preliminary studyåœ èj€ç³–æ£å"çš"å⊷è⁻•者ä,èj€æ,…nesfatinâ€1ä,Žé€‰å®šçš"ä	»£è ^d ¢å±é⊺	™©å›ç´ä¹‹é–-´a
46	Cardioprotective Effects of Nutraceuticals: Focus on Omega-3 Polyunsaturated Fatty Acids. Nutrients, 2021, 13, 3184.	4.1	4
47	Association of C-Reactive Protein and Other Markers of Inflammation with Risk of Complications in Diabetic Subjects. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2006, 17, 8-11.	0.7	3
48	Serum ANGPTL8 and ANGPTL3 as Predictors of Triglyceride Elevation in Adult Women. Metabolites, 2022, 12, 539.	2.9	3
49	Local Calcitriol Injections as a Suppressive Treatment of Secondary Hyperparathyroidism in Chronic Dialysis Patients. Renal Failure, 2007, 29, 941-945.	2.1	1
50	Low Serum 25-hydroxyvitamin D Level Does Not Adversely Affect Bone Turnover in Prepubertal Children. Nutrients, 2021, 13, 3324.	4.1	1
51	Microalbuminuria and risk of cardiovascular diseases in patients with diabetes and hypertension. Biochemia Medica, 0, , 25-34.	2.7	1
52	Response to "The Putative Role of Vitamin D in Essential Hypertension: Stepping Into the Light?â€: American Journal of Hypertension, 2014, 27, 987-988.	2.0	0
53	2021 PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on the diagnosis and therapy of lipid disorders in Poland. Diagnostyka Laboratoryjna I WiadomoÅci PTDL, 2021, 57, 1-99.	0.1	0